This is a research study to investigate how collecting information about treatment-related side effects directly from patients can help manage the side effects associated with certain oral chemotherapies in patients with metastatic renal cell carcinoma.

The purpose of this study is to learn more about the safety and effectiveness of the study drug (INCB057643) as monotherapy for participants with relapsed or refractory myelofibrosis.

If you or your child has been diagnosed with any cancer, you or your child may be able to take part in this study. This study will collect and store samples from you or your child so that researchers can use these samples and learn more about the disease.

If you or your child has been diagnosed with acute lymphoblastic leukemia (ALL), you or they might be able to take part in a research study. This study aims to understand why there are differences in outcomes in adolescents and young adults treated for ALL.

The purpose of this research study is to learn whether there are pre-treatment factors that impact quality of life and function 3 years or more after primary treatment of breast cancer. The factors we will look at in this study may include patient characteristics, specific breast cancer diagnosis, treatments, toxicities or adverse events during treatment.

If you are receiving your cancer treatment at an infusion space in North Carolina Basnight Cancer Hospital (NCBCH), you may be able to take part in a research study. This study aims to understand your satisfaction and experience in the infusion spaces during your treatment.

Do you have asymptomatic multiple myeloma, also known as smoldering multiple myeloma? You may be able to take part in a research study to help us learn more about the effectiveness of a drug called daratumumab in combination with lenalidomide and steroids.

In this study, we want to compare different combinations of drugs for patients with multiple myeloma who have not responded to previous treatment. We want to learn if an investigational medication may be beneficial for the treatment of multiple myeloma.

This study is being done to answer the following question: What are the effects (good or bad) of adding a study drug (duvelisib or CC-486 (azacitidine)) to the usual combination of drugs? We are doing this study because we want to find out if this approach is better or worse than the usual approach for T-cell lymphoma. The usual approach is defined as care most people get for peripheral T-cell lymphoma.

Have you been diagnosed with oropharyngeal (tonsil or tongue base) cancer. If so, you may be able to take part in a research study testing markers to determine who may be appropriate for less aggressive therapy and markers to determine if recurrent tumors can be detected earlier.